4//SEC Filing
Thye Dirk 4
Accession 0001209191-22-031515
CIK 0001662774other
Filed
May 22, 8:00 PM ET
Accepted
May 23, 8:29 PM ET
Size
10.2 KB
Accession
0001209191-22-031515
Insider Transaction Report
Form 4
Cortexyme, Inc.CRTX
Thye Dirk
DirectorCEO and CMO
Transactions
- Award
Common Stock
2022-05-19+64,589→ 64,589 total - Award
Employee Stock Option (right to buy)
2022-05-19+206,391→ 206,391 totalExercise: $0.55Exp: 2022-03-27→ Common Stock (206,391 underlying) - Award
Employee Stock Option (right to buy)
2022-05-23+1,979,650→ 1,979,650 totalExercise: $2.98Exp: 2032-05-22→ Common Stock (1,979,650 underlying)
Footnotes (3)
- [F1]On March 19, 2022, the Issuer completed acquisition (the "Merger") of Novosteo Inc. ("Novosteo"), pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022, (the "Merger Agreement"), by and among the Issuer, Quince Merger Sub I, Inc., a wholly owned subsidiary of the Issuer, Quince Merger Sub II, LLC, a wholly owned subsidiary of the Issuer, Novosteo, and Fortis Advisors LLC, solely in its capacity as the securityholders' representative. Pursuant to the terms of the Merger Agreement, at the closing of the Merger, the shares held by the Reporting Person in Novosteo were automatically cancelled and converted into the right to receive shares of common stock of the Issuer.
- [F2]The shares subject to the option shall vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments over the following three years.
- [F3]Received in the Merger in exchange for an employee stock option to acquire 2,266,500 shares of Novosteo common stock for $0.05 per share.
Documents
Issuer
Cortexyme, Inc.
CIK 0001662774
Entity typeother
Related Parties
1- filerCIK 0001638945
Filing Metadata
- Form type
- 4
- Filed
- May 22, 8:00 PM ET
- Accepted
- May 23, 8:29 PM ET
- Size
- 10.2 KB